Loading...

BMRN BIOMARIN PHARMACEUTICAL INC Business Restructuring 8-K Filing

BMRN

BMRN

BIOMARIN PHARMACEUTICAL INC

(BMRN)

2025 8-K

Trial Discontinuation

Financial Results Report

Major Debt Issuance

Debt Offering Announcement

BioMarin Financial Update

Financial Update

Treatment Discontinued

Merger Agreement Announcement

Management Change

Quarterly Earnings Report

Quarterly Financial Update

Financial Statements

Management Changes

Merger of Equals

Financial Statements

Bylaw Amendments

Board Appointment

Q4 Financial Results

Q3 Financial Results

Financial Guidance

Workforce Reduction

Management Change

Earnings Report

Annual Meeting Voting Results

Discontinuation of R&D Prog...

Earnings Reports

Settlement of Stockholder D...

Earnings Reports

Departure of Directors

Cooperation Agreement with ...

Retirement and Appointment

Earnings Reports

Earnings Reports

Annual Meeting Approval

Financial Results Announcement

Earnings Reports

Business Update at J.P. Mor...

External Links:

BioMarin Pharmaceutical Inc. reported expected acquired research and development charges of approximately $221 million, equating to a $1.10 impact on GAAP and non-GAAP diluted EPS for Q3 2025, due to their acquisition of Inozyme Pharma on July 1, 2025.

AI Assistant

BIOMARIN PHARMACEUTICAL INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.